Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord blood plasma
- Development stage
- Phase 2
- Administration
- Intravenous, Topical
01
Overview
Human umbilical cord blood plasma is a biological product derived from umbilical cord blood that contains various growth factors, cytokines, and immunomodulatory factors. It has demonstrated regenerative and anti-inflammatory properties in preclinical studies. HUCBP contains significantly lower levels of pro-inflammatory cytokines and higher levels of growth factors compared to adult blood plasma, contributing to its therapeutic potential. Key components include TIMP2 (tissue inhibitor of metalloproteinases 2), which has been shown to promote cognitive function in aged mice.
- Other names
- HUCBPUCB-PLCBPhUCP
02
Targets
MMP2 (Matrix metalloproteinase-2)TIMP2
Beyond the preview
Go deeper on human umbilical cord blood plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord blood plasma.